All About Multiple Sclerosis

More MS news articles for June 2004

Teva and Active Biotech Announce Agreement for Laquinimod

June 14, 2004
Source: Active Biotech AB

Teva Pharmaceutical Industries Ltd. and Active Biotech AB announced today that they have signed an agreement to develop and commercialize laquinimod, Active Biotech's novel immunomodulatory compound, which has the potential to be an orally available disease modifying treatment of multiple sclerosis (MS).

Copyright © 2004, PRNewswire